


GA 1645

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/198,723	
	Filing Date	November 24, 1998	
	First Named Inventor	Malcolm et al.	
	Group Art Unit	1645	
	Examiner Name	R. Zeman	
Total Number of Pages in This Submission	7	Attorney Docket Number	JB0800

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below) <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"> Appendix A attached to Amendment (2 pages) </div>
<div style="border: 1px solid black; padding: 5px; display: inline-block;"> RECEIVED AUG 03 2000 </div>		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Sandy Zaradic	
Signature		
Date	July 24, 2000	

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: July 24, 2000			
Typed or printed name	Sandy Zaradic		
Signature		Date	July 24, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

B



PATENT CASE: JB0800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

8/4/00
T. Gray

-----X
In re Application of: Malcolm *et al.* :
: For: Covalent Complexes of Hepatitis C Virus :
: NS3 Protease and NS4A Cofactor Peptide :
: Serial No.: 09/198,723 :
: Filing Date: November 24, 1998 :
-----X

Examiner: R. Zeman

Group Art Unit: 1645

RECEIVED

AUG 03 2000

TECH CENTER 1600-2230

July 24, 2000

Schering-Plough Corporation
Kenilworth, New Jersey 07033

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT

In response to the Office Action (Paper #10) dated June 15, 2000, please amend the application as follows:

In the Claims

- B¹.
1. (Amended) A covalent HCV NS4A-NS3 complex comprising [the] a central hydrophobic domain of native HCV NS4A peptide wherein the central hydrophobic domain comprises at least amino acid residues 22-30 of the native HCV NS4A peptide, a linker, and the HCV NS3 serine protease domain, wherein the hydrophobic domain of native HCV NS4A peptide is tethered by the linker to the amino terminus of the HCV NS3 protease domain.
 2. (Amended) The covalent HCV NS4A-NS3 complex of claim 1, wherein the linker comprises at least [about] 4 amino acid residues.
 3. (Amended) The covalent HCV NS4A-NS3 complex of claim 2, wherein the linker consists [essentially] of 4-6 amino acid residues.
 4. (Amended) The covalent HCV NS4A-NS3 complex of claim 3, wherein the linker consists [essentially] of about 4 amino acid residues.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on this 24th day of July 2000.

July 24, 2000
Date

Signature

Sandy Zaradic
Reg. No. 45,997

196

B